Roche's Oral SERD Giredestrant Fails Phase 3 persevERA Trial in First-Line Breast Cancer on March 11, 2026 giredestrant Malignant neoplasm of breast oral SERD persevERA PFS Roche (company) +
Roche's Giredestrant Fails Primary Endpoint in Phase 3 Breast Cancer Trial on March 09, 2026 Drops - Drug Form giredestrant Ibrance Malignant neoplasm of breast persevERA Phase 3 Clinical Trials Roche (company) +